Viewing data from:

TEMAZEPAM

ANDA

TEMAZEPAM | A071456 | NOVEL LABORATORIES INC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: RESTORIL(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 3 NDCs

Highest NADAC/Unit

$0.0786

per ea

Lowest NADAC/Unit

$0.0786

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
50268077915TEMAZEPAM 15 MG CAPSULE	$0.0786	EA	Generic	—	2026-06-17
67877014601TEMAZEPAM 15 MG CAPSULE	$0.0786	EA	Generic	—	2026-06-17
67877014605TEMAZEPAM 15 MG CAPSULE	$0.0786	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 4 NDCs (4 FSS)

Lowest Price

$7.43

Highest Price

$34.37

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
63629-8602-01TEMAZEPAM 15MG CAP	$7.43	FSS	Bryant Ranch PrePack DBA Bryant Ranch PrePack	04/30/2026
63629-8603-01TEMAZEPAM 15MG CAP	$34.37	FSS	Bryant Ranch PrePack DBA Bryant Ranch PrePack	04/30/2026
72162-1824-01TEMAZEPAM 15MG CAP	$7.43	FSS	Bryant Ranch PrePack DBA Bryant Ranch PrePack	04/30/2026
72162-1824-05TEMAZEPAM 15MG CAP	$34.37	FSS	Bryant Ranch PrePack DBA Bryant Ranch PrePack	04/30/2026

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain4 active DMFs4 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

CAMBREX PROFARMACO MILANO SRLTEMAZEPAM

DMF 43761981

FIS FABBRICA ITALIANA SINTETICI SPATEMAZEPAM

DMF 52231983

MATRIX PHARMACORP PRIVATE LTDTEMAZEPAM USP

DMF 231602009

R L FINE CHEM PVT LTDTEMAZEPAM

DMF 389982023

WYETH INCInactiveTEMAZEPAM

DMF 31931978

SANDOZ LTD PHARMACEUTICAL DIV CHEMICAL DEVELOPMENTInactiveTEMAZEPAM

DMF 55071984

WYETH-AYERST LABORATORIESInactiveTEMAZEPAM

DMF 61621986

CENTAUR PHARMACEUTICALS PVT LTDInactiveTEMAZEPAM USP

DMF 253642011

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 15MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Apr 21, 1987

No patent or exclusivity listings for this strength.